Development of ciprofloxacin-loaded poly(vinyl alcohol) dry powder formulations for lung delivery

Silva, Dina M.; Paleco, Roberto; Traini, Daniela; Sencadas, Vítor

doi:10.1016/j.ijpharm.2018.05.060

Cited by 18 publications

(9 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, by combining the data reported in this work with those of Della Bella et al, it is possible to study the correlation between resistance of the device (calculated according to Equation (3)) and FPF for both SS and BUD ( Figure S4 ). In agreement to data reported by Hassoun et al [ 37 ], no correlation seemed to exist for the hydrophilic model drug SS ( Figure S4, panel a ), while a clear linear correlation (R 2 = 0.997) was highlighted for the lipophilic drug BUD ( Figure S4 panel b ).…”

Section: Resultssupporting

confidence: 91%

“…The β form showed the narrowest particle size distribution with the majority of the particle having a size lower than 30 µm, while α and δ forms (as well as the hydrate) showed similar PSD with a median volume diameter around 23 µm. In view of a possible use of these powders as carriers in adhesive mixtures, it must be underscored that these figures are low compared to the typical median diameters of lactose carriers, which range between 10 and 150 µm, although specific lactose for inhalation, such as Respitose ® ML006 [ 37 ] having a PSD very similar to that of the mannitol particles reported here are available on the market.…”

Section: Resultsmentioning

confidence: 80%

See 1 more Smart Citation

Mannitol Polymorphs as Carrier in DPIs Formulations: Isolation Characterization and Performance

et al. 2021

View full text Add to dashboard Cite

The search for best performing carriers for dry powder inhalers is getting a great deal of interest to overcome the limitations posed by lactose. The aerosolization of adhesive mixtures between a carrier and a micronized drug is strongly influenced by the carrier solid-state properties. This work aimed at crystallizing kinetically stable D-mannitol polymorphs and at investigating their aerosolization performance when used in adhesive mixtures with two model drugs (salbutamol sulphate, SS, and budesonide, BUD) using a median and median/high resistance inhaler. A further goal was to assess in vitro the cytocompatibility of the produced polymer-doped mannitol polymorphs toward two lung epithelial cell lines. Kinetically stable (up to 12 months under accelerate conditions) α, and δ mannitol forms were crystallized in the presence of 2% w/w PVA and 1% w/w PVP respectively. These solid phases were compared with the β form and lactose as references. The solid-state properties of crystallized mannitol significantly affected aerosolization behavior, with the δ form affording the worst fine particle fraction with both the hydrophilic (9.3 and 6.5%) and the lipophilic (19.6 and 32%) model drugs, while α and β forms behaved in the same manner (11–13% for SS; 53–58% for BUD) and better than lactose (8 and 13% for SS; 26 and 39% for BUD). Recrystallized mannitol, but also PVA and PVP, proved to be safe excipients toward lung cell lines. We concluded that, also for mannitol, the physicochemical properties stemming from different crystal structures represent a tool for modulating carrier-drug interaction and, in turn, aerosolization performance.

show abstract

Section: Resultssupporting

confidence: 91%

Section: Resultsmentioning

confidence: 80%

Mannitol Polymorphs as Carrier in DPIs Formulations: Isolation Characterization and Performance

et al. 2021

View full text Add to dashboard Cite

show abstract

“…However, to overcome the hydrophobicity of PLGA or modulate the drug release, hydrophilic polymers such as PEG, PVA, HA can be employed to modify PLGA in the inhaled formulations 108 , 109 , 110 . Various polymeric excipients used in inhaled sustained-release formulations are summarized in Table 1 99 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 , 121 .…”

Section: Strategies To Extend the Pulmonary Exposure Of The Inhaled Medicinesmentioning

confidence: 99%

Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines

Guo

Bera

Shi

et al. 2021

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

Pulmonary administration route has been extensively exploited for the treatment of local lung diseases such as asthma, chronic obstructive pulmonary diseases and respiratory infections, and systemic diseases such as diabetes. Most inhaled medicines could be cleared rapidly from the lungs and their therapeutic effects are transit. The inhaled medicines with extended pulmonary exposure may not only improve the patient compliance by reducing the frequency of drug administration, but also enhance the clinical benefits to the patients with improved therapeutic outcomes. This article systematically reviews the physical and chemical strategies to extend the pulmonary exposure of the inhaled medicines. It starts with an introduction of various physiological and pathophysiological barriers for designing inhaled medicines with extended lung exposure, which is followed by recent advances in various strategies to overcome these barriers. Finally, the applications of the inhaled medicines with extended lung exposure for the treatment of various diseases and the safety concerns associated to various strategies to extend the pulmonary exposure of the inhaled medicines are summarized.

show abstract

“…Other linear polymers that have been used in relation to drug delivery include poly(vinyl alcohol) [ 115 ], poly(amino acids) [ 116 ], poly( N -(2-hydroxypropyl) methacrylamide) [ 117 ], and poly( N -vinyl-2-pyrrolidone) [ 118 ]. In addition, a few polysaccharides have also been under investigation, including chitosan [ 119 ], dextran [ 120 , 121 , 122 , 123 ], and hyaluronic acid [ 124 ].…”

Section: Linear Polymersmentioning

confidence: 99%

Telodendrimers: Promising Architectural Polymers for Drug Delivery

Mejlsøe

Kakkar

2020

Molecules

View full text Add to dashboard Cite

Architectural complexity has played a key role in enhancing the efficacy of nanocarriers for a variety of applications, including those in the biomedical field. With the continued evolution in designing macromolecules-based nanoparticles for drug delivery, the combination approach of using important features of linear polymers with dendrimers has offered an advantageous and viable platform. Such nanostructures, which are commonly referred to as telodendrimers, are hybrids of linear polymers covalently linked with different dendrimer generations and backbones. There is considerable variety in selection from widely studied linear polymers and dendrimers, which can help tune the overall composition of the resulting hybrid structures. This review highlights the advances in articulating syntheses of these macromolecules, and the contributions these are making in facilitating therapeutic administration. Limited progress has been made in the design and synthesis of these hybrid macromolecules, and it is through an understanding of their physicochemical properties and aqueous self-assembly that one can expect to fully exploit their potential in drug delivery.

show abstract

Development of ciprofloxacin-loaded poly(vinyl alcohol) dry powder formulations for lung delivery

Cited by 18 publications

References 47 publications

Mannitol Polymorphs as Carrier in DPIs Formulations: Isolation Characterization and Performance

Mannitol Polymorphs as Carrier in DPIs Formulations: Isolation Characterization and Performance

Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines

Telodendrimers: Promising Architectural Polymers for Drug Delivery

Contact Info

Product

Resources

About